Retinoblastoma Presentation, Treatment and Outcome in a Large Referral Centre in Tehran: A 10-Year Retrospective Analysis Publisher Pubmed



Faranoush M^{1, 2} ; Mehrvar N^{1, 3} ; Tashvighi M¹ ; Fabian ID⁴ ; Zloto O⁵ ; Bascaran C⁴ ; Ghorbani R⁶ ; Ghasemi F⁷ ; Naseripour M⁸ ; Sedaghat A⁸ ; Alebouyeh M¹ ; Mehrvar A^{1, 9} Show Affiliations
Source: Eye (Basingstoke) Published:2021

Abstract

Background/objectives: Early diagnosis, care and treatment of retinoblastoma is a challengeable issue for Iranian health system. This study was designed and conducted in a referral multidisciplinary centre in the capital city of Iran to evaluate management, care, prognosis and survival rates of paediatric patients with retinoblastoma. Methods: In this retrospective study, a total number of 309 patients younger than 15 years, diagnosed with retinoblastoma, who referred for diagnosis and treatment to MAHAK’s Pediatric Cancer Treatment and Research Center (MPCTRC) from 2007 to 2017 were evaluated. All data were analyzed via SPSS version 22 software in regard of parametric and non-parametric data. Survival rates were analyzed using the Kaplan–Meyer method. Results: The mean age of patients was 20 months and the majority of patients (77%) had leukocoria as a common clinical symptom at the time of diagnosis. Primary treatment methods were systemic chemotherapy (94%), laser (35%) and primary enucleation (28%). Relapses occurred in nearly 42% of cases, and the median time from diagnosis to the first relapse was 9 months. At the time analyzing the data, 11% of patients died. Patients’ 5-year OS and RFS rates were 79.6% and 41.5%, respectively. Conclusion: Comparing results with other conducted studies identifies that the recurrence rate was high in our considered patients. Also, OS and RFS rates in our study were not as considerable as other reports. Screening methods, updating protocols and follow-up of patients may lead to improvements in survival rates of patients with retinoblastoma. © 2020, The Author(s), under exclusive licence to The Royal College of Ophthalmologists.